← Eichor
Study identifier: NCT07435649 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

Condition: Central Nervous System Infection  ·  Sponsor: Delve Bio, Inc.

PhaseNA
Planned participants400
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Delve Bio, Inc. is a developer of novel mNGS tests with the goal of aiding in the diagnosis of infectious diseases in several clinical indications that may not have alternative traditional diagnostic methods routinely available. A proof of concept for the clinical utility of this mNGS testing methodology has been described in several seminal publications.1,2,3,4 Delve Bio is currently offering one of these assays as a laboratory-developed test (LDT) performed in a CLIA-certified, CAP-accredited laboratory. The test is called Delve Detect CSF. Delve Detect CSF is an mNGS in vitro diagnostic test intended for the simultaneous detection and differentiation of nucleic acids from multiple bacteria, viruses, fungi, and parasites in CSF from individuals suspected of meningitis or encephalitis. Delve Detect CSF identifies microbial nucleic acid in an unbiased and pathogen-agnostic manner. Historically, due to its cost and turnaround times, which can be on the order of 14 days, CSF mNGS testing is typically employed as a "test of last resort" for patients with suspected infectious meningitis and encephalitis, and is often used when traditional diagnostic methods cannot identify the cause of infection. In the IMPACT Study, we seek to investigate the diagnostic and clinical utility of mNGS testing if it is employed earlier in the diagnostic workup of patients with suspected CNS infection and unknown etiology in conjunction with a more rapid turnaround time for test results on the order…

This description comes directly from the study's public registry record.

Talk to the study team

Steve Miller, M.D., Ph.D.  ·  844-221-7423  ·  steve.miller@delve.bio

Timothy Blicharz, Ph.D.  ·  tim.blicharz@delve.bio

Always discuss trial participation with your own doctor first.

Locations (4)

University of California at San Francisco at Zuckerberg San Francisco GeneralSan Francisco, California, United StatesNot Yet Recruiting
Emory University HospitalAtlanta, Georgia, United StatesRecruiting
Lahey Hospital & Medical CenterBurlington, Massachusetts, United StatesNot Yet Recruiting
Vanderbilt University Medical CenterNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07435649